EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study

Giuseppe Neola iD, Fabiano Flauto iD, Carmine Caso, Giuseppina Montuori, Marco Maruzzo, Eleonora Lai, Giuseppe Luigi Banna iD, Michele Maffezzoli iD, Mimma Rizzo, Francesco Massari, Veronica Mollica, Sarah Scagliarini und 14 weitere

The Oncologist · 08.07.2026 · 31 (8)

DOI: 10.1093/oncolo/oyag256 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 02.07.2026. Verfasst von Giuseppe Neola und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131, Italy. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Urinary Bladder Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cisplatin-based neoadjuvant chemotherapy (NAC) improves survival in muscle-invasive urothelial cancer (MIUC), yet pathological complete response (pCR) is achieved in a minority of patients. Relative dose intensity (RDI) is a potentially modifiable determinant of chemotherapy efficacy, but its impact during NAC in MIUC remains unexplored.

Methods

This multicenter retrospective study included patients with MIUC treated with cisplatin–gemcitabine NAC followed by radical cystectomy. Relative dose intensity was calculated from original administration records and categorized as ≥85% vs <85%. The primary endpoint was pCR (ypT0N0M0). Secondary endpoints included overall survival (OS) and event-free survival (EFS).

Results

A total of 330 patients were included; 66% maintained RDI ≥ 85%. Overall pCR rate was 25.2%. Patients with RDI ≥ 85% achieved higher pCR rates compared with those with RDI < 85% (29.7% vs 16.2%; P = .008). Relative dose intensity ≥ 85% remained independently associated with pCR in multivariable analysis (odds ratio = 2.10; P = .032). Preserved RDI was also associated with improved EFS (hazard ratio [HR] = 0.65; P = .039) and OS (HR = 0.53; P = .026) at univariate analysis. Achievement of pCR was strongly associated with superior EFS (HR = 0.23; P < .001) and OS (HR = 0.35; P = .009).

Conclusion

Preservation of cisplatin RDI ≥ 85% during NAC is independently correlated with higher pCR rates and associated to a better survival trend in MIUC. Optimization of chemotherapy delivery represents a clinically actionable strategy to enhance neoadjuvant efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyUrinary Bladder NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansPathologic Complete ResponseFemaleRetrospective StudiesMaleAgedCisplatinMiddle AgedDeoxycytidineGemcitabine

Stichwörter der Autor:innen

bladder cancerneoadjuvantpathological complete responserelative dose intensityurothelial cancer

Substanzen

CisplatinDeoxycytidineGemcitabine

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131, Italy.
  • Portsmouth Hospitals University NHS Trust, Portsmouth, PO63LY, UK.
  • Oncology Unit 3, Istituto Oncologico Veneto - IOV IRCCS, Padova, 35128, Italy.
  • Faculty of Science & Health, School of Pharmacy & Biomedical Sciences, University of Portsmouth, Portsmouth, PO63LY, UK.
  • Department of Medicine and Surgery, University Hospital of Parma-Medical Oncology Unit, University of Parma, Parma, 43126, Italy.
  • Medical Oncology Unit, Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari, Bari, 70124, Italy.

ORCID-Profile: Giuseppe Neola, Fabiano Flauto, Giuseppe Luigi Banna, Michele Maffezzoli, Vincenza Conteduca, Davide Bosso, Alberto Servetto, Roberto Bianco, Luigi Formisano

Zitieren

APA

Neola, G., Flauto, F., Caso, C., Montuori, G., Maruzzo, M., Lai, E., Banna, G. L., Maffezzoli, M., Rizzo, M., Massari, F., Mollica, V., Scagliarini, S., Conteduca, V., Giannatempo, P., Rametta, A., Maiorano, B. A., Facchini, G., Lenci, E., Tambaro, R., …, & Formisano, L. (2026). The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag256

Vancouver

Neola G, Flauto F, Caso C, Montuori G, Maruzzo M, Lai E, et al. The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag256

BibTeX
@article{Neola2026,
  author = {Neola, Giuseppe and Flauto, Fabiano and Caso, Carmine and Montuori, Giuseppina and Maruzzo, Marco and Lai, Eleonora and Banna, Giuseppe Luigi and Maffezzoli, Michele and Rizzo, Mimma and Massari, Francesco and Mollica, Veronica and Scagliarini, Sarah and Conteduca, Vincenza and Giannatempo, Patrizia and Rametta, Alessandro and Maiorano, Brigida Anna and Facchini, Gaetano and Lenci, Edoardo and Tambaro, Rosa and Grillone, Francesco and Bosso, Davide and Crocetto, Felice and Imbimbo, Ciro and Servetto, Alberto and Bianco, Roberto and Formisano, Luigi},
  title = {The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {8},
  doi = {10.1093/oncolo/oyag256}
}
Kostenlos starten →